#1
|
|||
|
|||
Àäåêâàòíîå ôèíàíñèðîâàíèå - àäåêâàòíûé ðåçóëüòàò? Courage vs Anti-Courage?
Åæåãîäíûå ðàñõîäû íà íà DES â ÑØÀ ñîñòàâèëè 1,5 ìëðä USD.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îáûäåííûé âîïðîñ: Courage vs Anti-Courage îáñóæäàåòñÿ ñ íîâîé ñèëîé! Êîëëåãè, âàøå ìíåíèå? |
#2
|
|||
|
|||
Ñèëüíî ñìóòèëà ôðàçà:
"Number one, non-ACS patients represent the vast majority of coronary disease patients in the US, and number two, in patients who do not have ACS, it's very unclear that any of them should be getting PCI at all. The COURAGE trial, for example, suggested that PCI is no better than medical therapy in improving survival in patients who have stable angina. And then there are patients who don't even have angina, who have CAD but no symptoms, and certainly we don't think PCI helps those patients either. So if there is more PCI happening, and more costs associated with PCI, and most of those are occurring in a population that's not getting any survival benefit or quality-of-life benefit out of it, that is what's troubling." |
#3
|
|||
|
|||
Öèòàòà:
__________________
Ñ óâàæåíèåì |
#4
|
|||
|
|||
Òî÷íî!
"...in a population that's not getting any survival benefit or quality-of-life benefit out of it, that is what's troubling." Íåâíèìàòåëüíî ïðî÷èòàë! Ñïàñèáî!) |
#5
|
|||
|
|||
Öèòàòà:
![]() |
#6
|
||||
|
||||
Öèòàòà:
Íå ìîãó ïðåäñòàâèòü, áîëüøàÿ ðàçíèöà ïîëó÷èòñÿ èëè íåò. Ñòåíòèðîâàííûå ïàöèåíòû ìèíèìóì ãîä åäÿò êëîïè (÷àñòü íå ñòåíòèðîâàííûõ - òîæå), íî ÈÌÕÎ, ðàñõîä àíòèàíãèíàëüíûõ ïðåïàðàòîâ â ãðóïïå íå ñòåíòèðîâàííûõ äîëæåí áûòü âûøå. |
#7
|
|||
|
|||
Öèòàòà:
|
|
#8
|
|||
|
|||
À âîò, êñòàòè, ýêîíîìè÷åñêèå äàííûå Êóðàæà (ñì. íèæå). Íà ïðîòÿæåíèè èññëåäîâàíèÿ "îáñëóæèâàíèå" ÎÌÒ ãðóïïû áûëî ñòàáèëüíî íèæå íà 10-11ê$. Ïðàâäà íå î÷åíü ïîíÿòíî, ó÷èòûâàëèñü ëè â ýòîé ýêîíîìè÷åñêîé âûêëàäêå ïåðåõîäû ïàöèåíòîâ èç ÎÌÒ ãðóïïû â ãðóïïó PCI (êîòîðûõ áûëî îêîëî 30%...)
|
#9
|
|||
|
|||
Ðàñõîäû íà ìåäèêàìåíòû, êñòàòè, â îáåèõ ãðóïïàõ ïðàêòè÷åñêè ðàâíû.
|
#10
|
|||
|
|||
Öèòàòà:
__________________
Ñ óâàæåíèåì |
#11
|
||||
|
||||
|
#12
|
|||
|
|||
|
#13
|
|||
|
|||
Äåøåâûå ïîêðûòûå ñòåíòû - ýòî êîíå÷íî ïðîðûâ. Íî êðó÷å âñåõ áóäåò òàáëåòêà, ðàñòâîðÿþùàÿ áëÿøêè. Êàê òîëüêî ó ýòîãî ÷óäî-ëåêàðñòâà ïîÿâèòñÿ äæåíåðèê (è êàðäèîëîãèÿ çàêîí÷èòñÿ), ÿ ïîéäó çàíèìàòüñÿ ëàíäøàôòíûì äèçàéíîì.
|
#14
|
||||
|
||||
à êàê æå ñàìîðàññàñûâàþùèåñÿ ñòåíòû? áûëà íà ëåêöèè, ãäå ðàññêàçûâàëè ÷òî çà íèìè áóäóùåå....è åùå òàêèå êîñìè÷åñêèå êàðòèíêè, íàíîïîêðûòèÿ. ÿ âïå÷àòëèëàñü - êîñìîñ. èõ åùå íå âíåäðÿþò?
|
#15
|
||||
|
||||
Óâàæàåìàÿ Íàñòÿ! À îòêóäà òàêàÿ èðîíèÿ? Âðîäå áû â ABSORBE ðåçóëüòàòû âïîëíå ïðèìåëèìû. Äà è ñ íàíîïîêðûòèÿìè âñå íå òàê óæ ïëîõî? Âñå-òàêè ýòî îäèí èç âàðèàíòîâ áèîäåãðàäèðóåìîñòè ïîëèìåðà.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |